Dexrazoxane
Orphan DrugFDA Approved
Description
Dexrazoxane is a cardioprotective agent and chelating compound used to reduce the incidence and severity of cardiomyopathy associated with anthracycline chemotherapy. It is particularly relevant in preventing cardiac toxicity from topoisomerase II inhibitors used in cancer treatment. The drug acts as a topoisomerase II inhibitor itself and provides protection against DNA damage.
Indications & Therapeutic Use
Prevention of anthracycline-induced cardiomyopathy, treatment of anthracycline extravasation
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Dexrazoxane
| Generic Name | Dexrazoxane |
| Brands | 1 brand available |
| Active Ingredient | Dexrazoxane hydrochloride |
| Drug Class | Prevention of anthracycline-induced cardiomyopathy |
| Manufacturer | Pfizer |
| Dosage Forms | IV infusion, 500mg vial for reconstitution |
| Medical Code | V03AF02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00003263 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes